Conatus pharmaceuticals inc. (CNAT)
Income statement / TTM
Mar'20Dec'19Sep'19Jun'19Mar'19Dec'18Sep'18Jun'18Mar'18Dec'17Sep'17Jun'17Mar'17Dec'16Sep'16Jun'16Mar'16Dec'15Sep'15Jun'15Mar'15Dec'14Sep'14Jun'14Mar'14Dec'13Sep'13Jun'13Mar'13Sep'12Jun'12
Revenues:
Collaboration revenue

14,693

21,717

28,600

32,890

30,873

33,586

35,743

0

0

-

0

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Collaboration revenue

-

-

-

-

-

-

-

-

-

-

-

0

0

-

0

0

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Total revenues

14,693

21,717

28,600

32,890

30,873

33,586

34,982

36,882

38,116

35,377

26,572

17,006

0

-

0

0

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Operating expenses:
Research and development

14,210

23,527

31,580

36,498

38,670

41,368

43,393

44,894

47,375

43,220

38,832

32,493

23,521

20,294

18,010

17,288

17,112

16,297

15,450

15,744

15,141

14,908

14,492

11,980

9,630

6,947

5,744

4,978

0

0

0

General and administrative

11,138

10,196

10,186

10,833

10,373

10,495

10,268

10,057

9,657

9,707

10,859

10,479

10,523

10,337

8,683

8,571

8,327

7,833

7,961

8,022

7,865

7,379

7,575

6,664

5,497

4,650

3,264

2,806

0

0

0

Total operating expenses

25,348

33,723

41,766

47,331

49,043

51,863

53,661

54,951

57,032

52,927

49,691

42,972

34,045

30,631

26,694

25,860

25,440

24,130

23,412

23,766

23,007

22,288

22,067

18,644

15,127

11,598

9,009

7,784

0

0

0

Loss from operations

-10,655

-12,006

-13,166

-14,441

-18,170

-18,277

-18,679

-18,069

-18,916

-17,550

-22,320

-25,167

-26,248

-29,832

0

0

0

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Other income (expense):
Interest income

426

568

723

857

929

962

989

954

0

-

0

0

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Interest income

-

-

-

-

-

-

-

-

-

-

-

-

282

-

113

99

83

67

58

50

48

57

62

58

42

22

13

14

0

0

0

Interest expense

-

-

135

324

-

696

750

750

750

662

490

319

149

70

70

70

70

70

70

70

70

70

97

283

462

462

435

248

0

0

0

Other expense

-

-

-

-

-

-

-

-

-

-

-

-

0

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Other income (expense)

110

53

16

10

13

1

-23

-72

0

-

0

0

-

30

-3

-24

-13

-15

-17

-24

-27

-19

-6

16

13

-1

-11

-24

0

0

0

Other financing expense

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-3,576

-3,633

-3,538

0

0

0

Total other income

536

621

604

543

431

267

219

198

125

154

156

136

163

98

39

5

-0

-17

-28

-43

-48

-31

-41

-348

-3,435

-4,018

-4,066

-3,797

0

0

0

Net loss

-10,119

-11,385

-12,562

-13,898

-17,739

-18,010

-18,460

-17,871

-18,791

-17,396

-22,164

-25,030

-26,085

-29,734

-26,654

-25,854

-25,440

-24,148

-23,440

-23,810

-23,056

-22,319

-22,109

-18,992

-18,563

-15,616

-13,075

-11,581

0

0

0

Other comprehensive income (loss):
Net unrealized gains (losses) on marketable securities

-3

17

13

46

115

60

11

-19

-93

-71

-31

-40

-24

-2

8

28

8

9

7

-12

-0

-24

-18

2

-1

10

9

-2

0

0

0

Comprehensive loss

-10,122

-11,368

-12,549

-13,852

-17,624

-17,950

-18,449

-17,890

-18,884

-17,467

-22,195

-25,071

-26,109

-29,736

-26,645

-25,825

-25,432

-24,139

-23,433

-23,822

-23,056

-22,344

-22,127

-18,990

-18,564

-15,605

-13,065

-11,584

0

0

0

Net loss

-10,119

-11,385

-12,562

-13,898

-17,739

-18,010

-18,460

-17,871

-18,791

-17,396

-19,906

-22,378

0

-

0

0

-

-

-

-

-

-

-22,109

-18,992

-18,563

-15,616

-13,075

-11,581

0

0

0

Gain on extinguishment of convertible preferred stock

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

11,491

0

0

0

-

-

Deemed distribution from promissory note issuance

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

474

0

0

0

-

-

Net income applicable to participating securities

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

0

-

-

-

-

Net loss applicable to common stockholders

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-4,600

-7,978

-6,484

0

0

0

Net loss per share, basic and diluted

-0.10

-0.08

-0.10

-0.02

-0.14

-0.12

-0.15

-0.15

-0.17

-0.15

-0.13

-0.19

-0.14

-0.35

-0.31

-0.30

-0.35

-0.30

-0.31

-0.31

-0.38

-0.34

-0.42

-0.34

-0.34

-

-0.28

-

-2.17

-

-

Weighted average shares outstanding used in computing net loss per share, basic and diluted

33,170

33,173

33,170

33,168

33,165

31,128

30,190

30,114

30,048

30,078

30,004

28,103

26,163

26,021

22,410

21,542

20,626

19,881

19,668

19,338

15,581

15,549

15,508

15,445

15,412

-

11,664

-

1,060

-

-

Basic

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-2.55

-1.81

Diluted

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-2.55

-1.81

Basic

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

1,012

1,012

Diluted

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

1,012

1,012